4//SEC Filing
Lang Matthew 4
Accession 0001415889-25-005775
CIK 0001806952other
Filed
Feb 25, 7:00 PM ET
Accepted
Feb 26, 7:36 PM ET
Size
9.7 KB
Accession
0001415889-25-005775
Insider Transaction Report
Form 4
Lang Matthew
Chief Business Officer
Transactions
- Award
Common Stock
2025-02-10+112,500→ 162,500 total - Award
Option (right to buy)
2025-02-10+450,000→ 450,000 totalExercise: $0.55Exp: 2035-02-09→ Common Stock (450,000 underlying) - Award
Option (right to buy)
2025-02-10+56,250→ 56,250 totalExercise: $0.55Exp: 2035-02-09→ Common Stock (56,250 underlying)
Footnotes (3)
- [F1]12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date.
- [F2]12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.
- [F3]The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria.
Documents
Issuer
Lyell Immunopharma, Inc.
CIK 0001806952
Entity typeother
Related Parties
1- filerCIK 0001712069
Filing Metadata
- Form type
- 4
- Filed
- Feb 25, 7:00 PM ET
- Accepted
- Feb 26, 7:36 PM ET
- Size
- 9.7 KB